Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers
| Autor: | Edward Kanfer, Deshveer S Babra, Marcia Hall, Anand Sharma, Amir Yazdan, Priya V Joshi, Magdalene Joseph, Nikhil Vasdev, Andrew Gogbashian |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty General Biochemistry Genetics and Molecular Biology Carboplatin 03 medical and health sciences High dose chemotherapy 0302 clinical medicine Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Pharmacology Salvage Therapy business.industry Germ cell cancers Neoplasms Germ Cell and Embryonal Prognosis Transplantation 030220 oncology & carcinogenesis Female Stem cell business Stem Cell Transplantation Research Article |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 |
| Popis: | Background/Aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs. Patients and Methods: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes. Results: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2(nd) line chemotherapy was 17.3 months. Fourteen patients hadMedian survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance. Conclusion: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|